Gritstone bio (GRTS) shares fell as much as 38% in recent Thursday premarket activity after the clinical-stage biotechnology company said it made a Chapter 11 filing for bankruptcy.
The company said it is filing first day motions in its Chapter 11 case and plans to continue advancing its clinical programs throughout the court-administered restructuring process.
Price: 0.1230, Change: -0.08, Percent Change: -38.00
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments